This paper analyzes the ethical dimensions of Merck Pharmaceuticals' handling of Vioxx (rofecoxib), a non-steroidal anti-inflammatory drug withdrawn from the market in 2004 after evidence linked it to significantly elevated risks of heart attack and stroke. The paper examines the VIGOR clinical study, allegations that Merck suppressed cardiovascular risk data from a New England Journal of Medicine publication, and the company's conflict of interest in sponsoring its own safety research. It also evaluates the ethics of direct-to-consumer pharmaceutical advertising and critiques the FDA's approval process for allowing post-market rather than pre-market safety research. The paper concludes that while Merck's eventual withdrawal of Vioxx was appropriate, it came far too late to prevent tens of thousands of preventable cardiac events.
The paper demonstrates conflict-of-interest analysis in applied ethics: it identifies how Merck's financial stake in Vioxx's commercial success compromised the objectivity of both its internal research and the resulting publication, then connects this structural conflict to real patient harm. This technique — tracing how institutional incentives distort information — is central to pharmaceutical and business ethics writing.
The paper opens with background on Vioxx's development and FDA approval, then moves chronologically through the VIGOR study findings, the omission of data from the NEJM article, and internal corporate knowledge of risk. It pivots to two broader ethical questions — direct-to-consumer advertising and FDA pre-approval standards — before closing with a verdict on Merck's conduct. This case-to-principle structure is effective for applied ethics essays.
Rofecoxib, marketed under the brand name Vioxx, is a non-steroidal anti-inflammatory drug (NSAID) developed by Merck Pharmaceuticals as a treatment for osteoarthritis, acute pain conditions, and dysmenorrhea. The drug received FDA approval in 1999 and was subsequently brought to market. However, in 2004, Merck voluntarily withdrew Vioxx from the market due to evidence that the drug significantly increased patients' risk of heart attack and stroke.
The withdrawal of Vioxx followed the Vioxx GI Outcomes Research study (VIGOR), a scientific study comparing the efficacy and adverse-effect profiles of the drug. The results indicated a remarkable increase in heart attack risk among individuals taking Vioxx. When made aware of the findings, Merck argued that the results only demonstrated that naproxen — the comparator drug used in the study — had a protective effect against heart attacks. However, many scientists warned that this was an implausible argument, since naproxen would have had to be three times as effective as aspirin to account for the observed difference. Merck took no steps to investigate this claim further.
The results of the VIGOR study were submitted to the FDA, which subsequently ordered that all Vioxx packaging carry warning labels regarding the "increased risk of cardiovascular events." A preliminary version of the VIGOR results was later published by the New England Journal of Medicine (NEJM). However, after the article's preliminary publication, the journal's editors discovered that some data reported to the FDA had been omitted from the NEJM article. It was subsequently determined that this information had been clearly available to the article's authors, who included both independent researchers and Merck-hired writers. The omitted data concerned three additional heart attacks related to Vioxx use, which would have raised the relative risk associated with the drug from 4.25-fold to 5-fold.
You’re 37% through this paper. Sign up to read the remaining 4 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.